

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

EXERCISE OF PUT OPTION

This announcement is made pursuant to Rule 14.74(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of EC Healthcare (the “**Company**”) dated 10 December 2024 (the “**Announcement**”) in relation to, among others, the grant of the Put Option by the Purchaser, an indirect wholly-owned subsidiary of the Company, to the Seller in respect of its equity interests in the Target Company pursuant to the Agreement. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Seller was granted the Put Option, pursuant to which it may request the Purchaser to purchase from it all of the shares of the Target Company held by it as at the date when the Put Option is exercised with the Put Option Exercise Price.

On 21 April 2026, the Seller served a written notice to the Purchaser to exercise its Put Option to sell its entire shareholding in the Target Company, being approximately 10% of the total issued share capital of the Target Company, to the Purchaser in accordance with the terms of the Agreement.

Based on the FY25 Cash EBITDA as agreed by the Purchaser and the Seller, the Put Option Exercise Price is HK\$6,000,000. It is intended that the Put Option Exercise Price shall be funded by the internal resources of the Group.

The exercise of the Put Option by the Seller will not have any impact on the business and operations of the Target Company. Following the completion of the acquisition of equity interests in the Target Company pursuant to the Put Option granted to the Seller, the Target Company will become wholly-owned by the Group. The Target Company will continue to be accounted for as a subsidiary of the Company.

By order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 21 April 2026

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie and Mr. Lee Heung Wing; the non-executive Directors are Mr. Luk Kun Shing Ben and Mrs. Leung Yang, Shih Ti Marianne; and the independent nonexecutive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.